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A total of seven blood group antigens were added to four of the current blood group systems (Table 1) . Three new blood group systems were created, one de novo (CD59), and two others Vel (VEL) and Augustine (AUG), elevating the previously homeless high-incidence antigens Vel and At a , respectively. This brings the current total of 
New blood group antigens

System 2: MNS
Two antigens have been added to the MNS system. Exome sequence analysis of samples from SARA+ and SARA-family members [1] identified a single nucleotide change c.240G>T in exon 3 of GYPA, which changes p.Arg80Ser. Sequence analysis of unrelated SARA+ samples confirmed the causative polymorphism [2] . The provisionally assigned number MNS47 was ratified by the working party and the low-prevalence series number 700052 has been made obsolete.
Molecular characterization of the GP.Kip and GP.Yak hybrid glycophorins showed that they were one and the same and are encoded by the same GYP(B-A-B) hybrid that produces Mur, Hil, MUT, MINY, as well as the antigen KIPP [3, 4] . KIPP is recognized by the anti-Hop+Nob sera, Anek and Raddon, but not by antisera specific for the Hop or Nob antigens; as well as by the original antiKipp serum [5] . The resulting GP(B-A-B) hybrid retains p.Ser51, which distinguishes this hybrid protein from other known GP(B-A-B) hybrids, which have p.Tyr51. The provisionally assigned number MNS48 was ratified by the working party.
System 5: Lutheran
A new high-prevalence antigen, LUIT was assigned to the Lutheran blood group system based on the serology (LU23) and the identification of two changes in LU: sequencing showed two novel homozygous mutations, one in exon 4, c.469G>A (p.Gly157Arg), and one in exon 10, c.1289C>T (p.Thr430Ile). [6] . There was insufficient A second new high-prevalence antigen named LUGA (LU24) was assigned to Lutheran based on the serology and the identification of a single missense change c.212G>A (p.Arg71His) in exon 3 of LU [7] . The proband's plasma failed to react with Lu:À12 and Lu:À17 RBCs, as well as Lu(aÀbÀ) RBCs and her own cells. However, antiLu12 could be excluded since the RBCs of the proband were reactive with anti-Lu12, and anti-Lu17 could be excluded based on the sequencing results which predicted homozygosity for Lu17. The serology may also be explained in part by the location of the novel amino acid change, which is predicted to lie in the first extracellular immunoglobulin domain of the Lu glycoprotein that also expresses Lu12, LURC, Lu a /Lu b , Lu21, Lu5 and Lu17. In addition, homozygosity for two silent changes were observed in exon 6 (c.711C>T and c.714C>T).
System 14: Dombrock
Two new high-prevalence antigens were assigned to the Dombrock blood group system, based both on serology and molecular analysis. The first, named DOLC, was based on the serology (DO9) and the identification of the c.566C>T (p.Thr189Met) change in exon 2 of DO. The proposita's RBCs typed Do(a+bÀ), Hy+, Jo(a+), DOYA+, DOLG+ and her plasma was non-reactive with Gy(aÀ) RBCs and only weakly reactive with HyÀ RBCs [8] .
Similarly, an antibody with serological characteristics consistent with Dombrock antibodies, in that it was nonreactive with trypsin-treated RBCs and weakly reactive only with DTT-treated RBCs, was shown to be directed at a new high-prevalence antigen, subsequently named DODE. Molecular analysis identified a c.405C>A (p.Asp135Glu) change in exon 2 of DO [9] . The antigen was assigned as DO10.
System 28: GLOB PX2, a carbohydrate antigen belonging to the GLOB collection (209) and determined by a terminal ß3-N-acetylgalactosamine added to paragloboside, was shown to be the product of B3GALNT1, also known as the P antigen synthase [10] . PX2 was therefore reclassified as a member of the GLOB blood group system (028). The P antigen was previously assigned the name GLOB1 (028001), and thus, PX2 was named GLOB2 (028002). This leaves LKE as the sole remaining antigen in the GLOB (209) collection, and the former PX2 number, 209004, was made obsolete.
New blood group systems
System 34: VEL A founder mutation in the previously undescribed small integral protein 1 (SMIM1) gene, c.64_80delGTCAGCC-TAGGGGCTGT, was identified as the primary molecular basis underlying the VelÀ phenotype [11] [12] [13] . The presence or absence of Vel antigen was directly correlated to the presence or absence of SMIM1, a single-pass integral membrane protein. The considerable variation in antigen strength was shown not only to correlate with zygosity for the wild-type SMIM1 but could also be affected by two rare missense mutations, c.152T>A and c.152T>G (encoding p.Met51Lys and p.Met51Arg, respectively). Furthermore, a single nucleotide polymorphism in intron 2 (rs1175550) situated in a GATA-1 binding site also considerably influenced Vel antigen expression [12, 14, 15] .
Based on the molecular and biochemical evidence, Vel was assigned blood group system status (034); system name: Vel; symbol: VEL, antigen: VEL1 (034001). There was no molecular evidence that ABTI was dependent on SMIM1 for expression, despite historical serological evidence of a phenotypic association [16] . As a consequence, collection 200212 was made obsolete and ABTI was returned to the 901 series and reassigned its old number (901015) .
As yet, the function of SMIM1 remains unknown; however, elegant work by Arnaud and colleagues has suggested the protein to be a type 2 integral membrane protein [17] .
System 35: CD59
Based on the publication of a case report in which a young patient with a CD59 deficiency produced an alloantibody specific for CD59, blood group status was unanimously assigned [18] [19] [20] . Both the blood group system and symbol are CD59 (035), and the antigen defined by the antibody maker in this case report has been named CD59.1.
System 36: AUG
The erythrocyte protein, equilibrative nucleoside transporter 1 (ENT1), was identified as the carrier of the At a antigen. Daniels and colleagues showed that the At(aÀ) phenotype in individuals of African origin is defined by an amino acid polymorphism on the ENT1 protein (c.1171G>A; p.Glu391Lys) and that the At(aÀ) members of a family affected by bone malformation lacked the protein due to an inactivating mutation in the ENT1 gene: c.589+1G>C [21] . Based on the evidence, and following a discussion on names, the blood group system Augustine (symbol AUG) was created (036). The antigen defined by the antibody produced by the null phenotype was named AUG1, and the antigen defined by the amino acid Glu391 (At a ) was named AUG2.
Gene terminology
The Working Party continues to update the allele nomenclature tables and these can be found on the ISBT website.
(http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/) We anticipate an expansion of these tables, and a more detailed monograph on guidelines and usage is planned. 
